Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Eur J Clin Pharmacol. 2024 Jun;80(6):855-867. doi: 10.1007/s00228-024-03656-y. Epub 2024 Feb 28.
To examine the associations between use of statins and risks of various ovarian, uterine, and cervical diseases, including ovarian cancer, endometrial cancer, cervical cancer, ovarian cyst, polycystic ovarian syndrome, endometriosis, endometrial hyperplasia, endometrial polyp, and cervical polyp.
We conducted a cohort study among female participants in the UK Biobank. Information on the use of statins was collected through verbal interview. Outcome information was obtained by linking to national cancer registry data and hospital inpatient data. We used Cox proportional hazards regression to examine the associations.
A total of 180,855 female participants (18,403 statin users and 162,452 non-users) were included. Use of statins was significantly associated with increased risks of cervical cancer (adjusted hazard ratio (HR), 1.55; 95% confidence interval (95% CI), 1.05-2.30) and polycystic ovarian syndrome (adjusted HR, 4.39; 95% CI, 1.68-11.49). However, we observed no significant association between use of statins and risk of ovarian cancer, endometrial cancer, ovarian cyst, endometriosis, endometrial hyperplasia, endometrial polyp, or cervical polyp.
Our findings suggest that use of statins is associated with increased risks of cervical cancer and polycystic ovarian syndrome, but is not associated with increased or decreased risk of ovarian cancer, endometrial cancer, ovarian cyst, endometriosis, endometrial polyp, or cervical polyp.
研究他汀类药物的使用与各种卵巢、子宫和宫颈疾病（包括卵巢癌、子宫内膜癌、宫颈癌、卵巢囊肿、多囊卵巢综合征、子宫内膜异位症、子宫内膜增生、子宫内膜息肉和宫颈息肉）风险之间的关联。
我们在英国生物银行的女性参与者中开展了一项队列研究。通过口头访谈收集他汀类药物使用信息。通过与国家癌症登记数据和医院住院数据链接获取结局信息。我们使用 Cox 比例风险回归来检验关联。
共纳入 180855 名女性参与者（18403 名他汀类药物使用者和 162452 名非使用者）。他汀类药物的使用与宫颈癌（调整后的危险比（HR），1.55；95%置信区间（95%CI），1.05-2.30）和多囊卵巢综合征（调整后的 HR，4.39；95%CI，1.68-11.49）风险的增加显著相关。然而，我们未观察到他汀类药物的使用与卵巢癌、子宫内膜癌、卵巢囊肿、子宫内膜异位症、子宫内膜增生、子宫内膜息肉或宫颈息肉风险之间存在显著关联。
我们的研究结果表明，他汀类药物的使用与宫颈癌和多囊卵巢综合征风险的增加相关，但与卵巢癌、子宫内膜癌、卵巢囊肿、子宫内膜异位症、子宫内膜息肉或宫颈息肉风险的增加或降低无关。
